Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo by Nagasawa Joji et al.
Novel HER2 selective tyrosine kinase
inhibitor, TAK-165, inhibits bladder, kidney
and androgen-independent prostate cancer in
vitro and in vivo
著者 Nagasawa Joji, Mizokami Atsushi, Koshida


















Blackwell Publishing AsiaMelbourne, AustraliaIJUInternational Journal of Urology0919-81722006 Blackwell Publishing Asia Pty LtdMay 2006135585590Original Article
 

















Integrative Cancer Therapy and Urology, Kanazawa Univer-
sity Graduate School of Medicine, 13-1 Takara-machi,
Kanazawa, Ishikawa, Japan. 
Email: mizokami@med. kanazawa-u.ac.jp
Received 10 February 2005; revision 7 August 2005; 




Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits 
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: TAK-165 is a new potent inhibitor of human epidermal growth factor receptor 2 (HER2) tyrosine kinase. Several reports
suggest HER2 expression in bladder cancer, renal cell carcinoma (RCC) and androgen-independent prostate cancer. We therefore


















 in volume, mice were orally administered TAK-












: HER2 expression was observed in HT1376, UMUC3, T24 (bladder), ACHN (kidney), DU145, LNCaP, LN-REC4






















mol/L). In the xenograft model,









 100) after 14 days treatment were 22.9%, 26.0%, and












Human epidermal growth factor receptor (EGFR; HER1,
erbB1), human epidermal growth factor receptor 2 (HER2;
erbB2), HER3 (erbB3) and HER4 (erbB4) are members of
the ErbB family of transmembrane receptor tyrosine
kinases. The ErbB receptors are expressed in a variety of
tissues of epithelial, mesenchymal and neuronal origin,





 Deregulated expression of
receptors, in particular EGFR and HER2, has been impli-
cated in the development and malignancy of numerous
types of human cancers, and EGFR and HER2 have
become a potential target for therapy. A humanized anti-





 and a tyrosine kinase inhibitor of
ErbB1 (ZD1839) has been approved for therapy of




In urological cancer, bladder cancer, prostate cancer and





particular, bladder cancer and androgen-independent pros-
tate cancer are reported to express HER2 frequently. In
advanced cases, these cancers are untreatable by conven-
tional therapy and new drugs are desired. So we studied





In the present study, we confirmed TAK-165 efficacy on













Inhibitor, antibody, and growth factors
 
The HER2 tyrosine kinase selective inhibitor, TAK-165
was synthesized by Takeda Chemical Industries (Osaka,
Japan). Anti-HER2 monoclonal antibody Trastzumab was
purchased from Roche (Tokyo, Japan). The following anti-
bodies were used for immunoblot analysis: anti-HER2
(CB11) from PROGEN (Heidelberg, Germany), EGFR




(1005), HER3 (C-17) and HER4 (C-18) from Santa Cruz
Biotechnology (Santa Cruz, CA, USA), monoclonal anti-
phospho-tyrosine (clone 4G10) and antibodies against
EGFR, PDGFR and FGFR from Upstate Biotechnology
(Lake Placid, NY, USA) and phospho-HER2/erbB2 spe-





Akt, anti-p44/42 MAP kinase and anti-phospho-p44/42





The human bladder cancer cell line T24, renal cell carci-
noma cell line ACHN, androgen-dependent prostate cancer
cell line LNCaP, androgen-independent prostate cancer
cell line DU-145, PC-3, and breast cancer cell line BT474
were obtained from the American Type Culture Collection
(ATCC). Bladder cancer cell lines HT1376 and UMUC-3
were purchased from Dainippon Laboratories (Osaka,
Japan). LN-REC4 cell line is a derivative of LNCaP cell
line but which has grown well in the castrated SCID mouse
after two passages in castrated mouse. BT474, LNCaP and
LN-REC4 were cultured in RPMI1640 containing 10%








atmosphere and the other cell lines were maintained in
Dulbecco’s modified Eagle’s medium containing 10%
FBS. Human embryonic normal fibroblasts, MRC-5, were
obtained from the RIKEN cell bank (Wako, Japan) and
cultured in Eagle’s minimum essential medium (EMEM)
with 10% FBS, glutamine, penicillin and streptomycin.
A431, Jurkat, Namalwa and NIH3T3 cells were also pro-
cured from the ATCC.
 
Measurement of tyrosine kinase activity and 
downstream cascade of HER2
 
The activity of HER2/erbB2 tyrosine kinase and other
receptor-type or non-receptor-type tyrosine kinase activi-
ties, and autophosphorylation were measured by western
blotting methods. To determine HER2/erbB2 tyrosine









were seeded on 24-well plates and cultured overnight.
TAK-165 was then added at various concentrations. After
incubation for 2 h, the cells were harvested directly into





determine other receptor-type tyrosine kinase inhibition,









were seeded in medium containing 10% FBS and incu-
bated overnight to allow the cells to adhere to the plates.
The medium was replaced with serum-free medium, and
the cells were allowed to grow for another day. TAK-165
was added 2 h before the addition of growth factors (A-
431cells: EGF [20 ng/mL]; NIH3T3 fibroblasts: PDGF
[20 ng/mL] or FGF [20 ng/mL]). After incubation for
5 min, the cells were lyzed in SDS-sample buffer. To deter-
mine non-receptor-type tyrosine kinase inhibition, A-431,








 cells/well) were used.
After incubation with TAK-165 for 2 h, the cells were
directly harvested into SDS-sample buffer. Aliquots con-
taining equal amounts of total cell extract were run on
7.5% to 15% gradient SDS–polyacrylamide gel electro-
phoresis (PAGE). Following electrophoresis, proteins were
transferred onto a polyvinylidene fluoride (PVDF) mem-
brane, for western blot analysis using a relevant primary
antibody. Detection of protein was accomplished by an
enhanced chemiluminescent (ECL) detection method. The
extent of tyrosine phosphorylation of HER2/erbB2, other
tyrosine kinases, and phospho-protein were measured by
the LAS-1000 plus lumino-image analyser (Fuji Film,
Tokyo, Japan). The concentration of TAK-165 that inhibits





) was calculated from a dose–response curve gener-
ated by least-squares linear regression of the response
using SAS software (SAS Institute, Cary, NC, USA).
Effects of TAK-165 on Akt and MAPK activity, a well-
known downstream pathway of HER2, were evaluated in
BT474 using antibodies described above.
 
Analysis of HER family members expression in 
cell lines
 
To characterize the expression of HER families among cell
lines, cells were washed twice with ice-cold phosphate-
buffered saline (PBS), lyzed with RIPA buffer (10 mM
sodium phosphate [pH 7.2], 150 mM NaCl, 0.1% SDS, 1%
NP-40, 1% sodium deoxycholate, and protease inhibitors),
collected by scraping, and cleared by centrifugation. Fifty
micrograms of protein were electrophoresed on a 7%
SDS–PAGE gel, transferred to PVDF membrane (Bio-Rad
Laboratories, Hercules, CA, USA) and subjected to immu-
noblot analysis. Immunoreactive bands were detected
using chemiluminescence (Pierce, Rockford, IL, USA).
 










) were seeded into 6-well plates and cul-









C. TAK-165 was then added at various concentrations,
and the cells were treated continuously for 3 days. After
the incubation period, cells were counted. The data is aver-




 value was calculated from
a dose–response curve generated by least-squares linear
regression of the response.
 
Xenograft studies in mice
 





) and SCID mice (C.B.-17 Scid/Scid).
UMUC-3 and ACHN cells were implanted subcutaneously
to nude mice. Castration was performed on SCID mice
1 week before implantation of LN-REC4 cells. UMUC-3
and LN-REC4 cells were implanted with 50% Matrigel
solution (Becton Dickinson, Franklin Lakes, NJ, USA).










the mice were treated orally twice daily for 14 days with
vehicle (control) or 10 or 20 mg/kg per day of TAK-165.
In the Herceptin study against UMUC-3, treatments con-
sisted of a twice weekly intraperitoneal injection of 20 mg/
kg Herceptin in PBS for 2 weeks. Tumor growth was
assessed by electronic caliper measurement of tumor diam-
eter in two dimensions, and tumor volume was calculated





















where A is the largest diameter of the tumor and B is the
smallest diameter of the tumor. Tumor size was measured
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every 2 days throughout the study period. The antitumor
effect was expressed as growth of each treated tumor/








TAK-165 inhibits HER2 phosphorylation and 
its down-stream Akt and MAPK in HER2 





We first confirmed the effects of TAK-165 on HER2, Akt
and MAPK phosphorylation using HER2 strongly express-
ing cell line (BT474). PI3K and MAPK pathway are well




 PI3K-Akt pathway is
associated with inhibition of apoptosis, and MAPK path-
way is also associated with cell growth. TAK-165 inhibited





phosphorylation of Akt and MAPK1 have also been suffi-
ciently inhibited (Fig. 1).
 
TAK-165 selectively inhibits HER2 tyrosine 
kinase
 
To confirm TAK-165 selectivity, we examined influences
of TAK-165 on the other tyrosine kinase activity. TAK-165





and did not inhibit other types tyrosine kinase up to
25 000 nmol/L (Table 1).
 
Expression profiles of HER families in bladder, 
kidney and prostate cancer cell lines
 
In order to see the level of HER family protein expression,
western blot analysis of HER family protein was carried
out. As shown in Figure 2, three bladder cancer cell lines
(HT1376, UMUC-3, and T24) expressed HER2 weakly.
ACHN renal cell carcinoma cell line and four prostate
cancer cell lines (DU145, PC-3, LNCaP, and LN-REC4)
also expressed HER2. However, PC-3 cells expressed
HER2 very faintly. There was no significant difference in
HER2 expression between androgen-dependent LNCaP
and its derivative androgen-independent cell line LN-
REC4.
 
Sensitivity to TAK-165 in vitro
 




, after cells were
treated with TAK-165 at various concentrations continu-





ues of these cells were calculated. Most of cell lines
studied this time indicated good TAK-165 sensitivity
despite of weak HER2 expression (Table 2). Generally,
TAK-165 sensitivity depends on HER2 levels of each cell
line. Especially, BT474 cells which over-express HER2


















mol/L). But, HT1376 and ACHN cells that





















Inhibition of HER2, Akt and MAPK phosphorylation
by TAK-165 in BT474 (HER2 over-expressing cell line).
BT474 cells were treated with TAK-165 for 2 h at indicated
concentration. Then cell lysates were prepared and analysed
for phosphorylation of HER2, Akt and MAPK by western blot
























































 values (nmol/L) in the table were calculated from
dose–response curves generated by least-squares linear
regression of the response using SAS software. Values in








Expression profiles of HER family kinases in bladder,
kidney and prostate cancer cell lines. Total protein were
extracted from cell lysates and then western blots were per-




g). Lane 1, BT474; Lane 2, HT1376;
Lane 3, UMUC-3; Lane 4, T24; Lane 5, ACHN; Lane 6,
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During our study of HER2 inhibitor on urological cancer,
we first have studied the antitumor effect of Herceptin





 in mice, 20 mg/kg of Herceptin or vehicle
were administered intraperitonealy twice per week for
2 weeks. Herceptin was ineffective to UMUC-3 tumor
growth (Fig. 3a). Then next, we administered 10 mg/kg per
day or 20 mg/kg per day TAK-165 twice daily for 2 weeks.
TAK-165 significantly inhibited growth of UMUC-3 cells









(Fig. 3c) and there were even some cases that tumor has
disappeared and did not recur for several weeks after
14 days of treatment (data not shown). LN-REC4 was also

















1 BT474 (Breast) 0.005














5 ACHN (Kidney) 25<
6 DU145 (Prostate) 1.647
7 PC-3 (″) 4.620
8 LN-REC4 (″) 0.090
9 LNCaP (″) 0.053
Cells were treated with TAK-165 at various concentrations
for 72 h. After the incubation period, the cells were counted.
The IC50 value was calculated from a dose–response curve
generated by least-squares linear regression of the response.
The data were obtained from average of triplicates.
Fig. 3 Response of xenograft tumors to TAK-165 and Herceptin treatment. (a) Herceptin (20 mg/kg twice per week) or
phosphate-buffered saline (control) was administered to mice bearing UMUC-3 (bladder cancer). (b–d) TAK-165 (10 mg/kg per
day or 20 mg/kg per day) or vehicle was orally administered for continuously 14 days to mice bearing UMUC-3 (b), ACHN (c)
(renal cell carcinoma), and LN-REC4 (d) (androgen independent prostate cancer) (n = 6–8 per group). Results are given as mean
tumor volume ± SD.
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control tumor volume ratio were 22.9%, 26%, 26.5% in
UMUC-3, ACHN and LN-REC4, respectively. There was
no statistical difference of antitumor effect between 10 mg/
kg per day and 20 mg/kg per day TAK-165 treated groups.
Concerned with side-effects, there were two deaths in
TAK-165-treated groups (total 54 treated with TAK-165)
and two deaths in the control group (total 22, treated with
PBS). Weight loss was also observed, but it was less than
10% of treated animals and there was no statistical dif-
ference between TAK-165 and control group. These side-
effects may have been caused by compulsory oral
administration of compound. These data showed efficacy
and safety of TAK-165.
Discussion
Recently, Herceptin was administered to patients with
androgen-independent prostate cancer or with advanced
bladder cancer as a single agent or in combination with
chemotherapeutic agents.10–12 In the reports, the efficacy of
Herceptin alone was limited.13 Because in urological can-
cers, HER2 is not expressed so strongly as breast cancer,
such data might be natural. In this study, we compared the
efficacy of TAK-165 with Herceptin in UMUC3 which
express HER2 very weakly. Although the reason is
unknown, TAK-165 significantly inhibited tumor growth
as compared with Herceptin. One possible reason is that
Herceptin did not show a quick effect over the 14-day
observation period because it requires an immunological
response. But another reason will also exist. In the ACHN
study, TAK-165 was ineffective in vitro (IC50 > 25 μM),
but tumor growth was significantly inhibited in vivo. The
degree of HER2 expression was not changed between in
vitro and in vivo (data not shown). Although the high selec-
tivity of TAK-165 for HER2 tyrosine kinase has been
proved in vitro, we have to investigate in vivo selectivity
and if there are other mechanisms of tumor suppression.
In the in vivo study, we could not observe dose-
dependent effects of TAK-165 between a dose of 10 mg/
kg per day and 20 mg/kg per day (Fig. 3). We think the
10 mg/kg per day of TAK-165 was enough to inhibit tumor
growth. In the BT474 study, a dose-dependent effect was
observed between 5 mg/kg per day and 10 mg/kg per day
of TAK-165 (data not shown).
Because HER2 is not playing so crucial a role for sur-
vival or proliferation of cancer cells in most urological
cancers compared with strongly expressed HER2 breast
cancer, TAK-165 might need some combination to increase
its efficacy. Combination with specific inhibitors that spe-
cifically targets oncoprotein is ideal for efficacy and safety.
Combination with EGFR tyrosine kinase inhibitor or anti-
EGFR antibody is one of the candidates. Zhou et al.
reported a synergic effect of this combination in colon
cancer.14 Combination of Herceptin with a COX-2 inhibitor
has also been reported, but the effect was limited.15 Real-
istically, combination with conventional cytotoxic agents
will be the first candidates for combination with TAK-165.
Herceptin with paclitaxel or doxorubicin has proved syn-
ergic efficacy in experiments and has improved prognosis
of patients with metastatic breast cancer.16,17 We are now
studying combinations with taxanes. Combination with
radiation is also to be studied. Recently anti-HER2 mono-
clonal antibody has been proved to enhance radiosensitiv-
ity of esophageal cancer.18
In this study, we confirmed high selectivity of TAK-165
and high efficacy against bladder cancer, renal cell carci-
noma and prostate cancer. Although there remains many to
study about TAK-165, TAK-165 is a hope for urological
cancer treatment.
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